The COVID19 vaccine and market implications

It has been over a year since the first cases of COVID-19 were diagnosed in Wuhan, China. As a result of the virus, we have seen an unfathomable global shutdown in Q2, followed by a record-setting return to growth in Q3 as the summer months arrived. Q4 resulted in second and third waves. In November, results of Phase 3 vaccine studies began to trickle in and by the end of the year, frontline workers and those most in need were already receiving the first doses.

US Annualised GDP Growth Rate:

Source: Trading Economics, BLS

The first few months of 2021 will likely continue in the same manner as 2020 ended:

threats of global lockdowns and restrictions as the virus lingers
depressed economic data, primarily in services
additional fiscal and monetary support from governments and central banks around the world

As we move into Q2 and the vaccines become more widely available, things should begin to return to the “old normal.” However, although a return to the “old normal” may be better for daily life, it may not be so great for the markets. As we move through 2021, below are some markets to watch as the vaccine is dispersed:

Economic Data outlook

As we progress through the year, employment should pick up and initial claims should decrease. As people return to work after being cooped up for the better part of a year, PMIs should continue to recover, especially in the services industries. Industries such as food services, cruise lines, airlines, and hospitality could outperform. The “stay at home” industries, such as technology (which includes FAANG stocks) may underperform. GDP should continue to rise – however, the growth rate may begin to level off towards the end of the year. Housing should stay strong on the back of a demographic tailwind and millennials seeking to “beat the rush” in anticipation of higher interest rates.

The Covid 19 impact on the US Dollar

With a vaccine on the way and more people returning to work, there will be less need for fiscal and monetary stimulus; however many central banks have indicated that they will keep monetary policy accommodative through 2021. The US Dollar could remain under pressure through the first half of the year but may rebound heading into Q3 and Q4 as the FOMC may hint at raising interest rates if inflation picks up heading into in 2022.

To put it simply, better economic data equals less stimulus. Less stimulus means less US Dollars in the system. Less US Dollars (plus higher demand for products and services) equals higher price.

On a monthly timeframe, the DXY has broken below the upward sloping trendline from September 2011. If that level breaks, watch for the 50% retracement level from the February 2008 lows to the January 2017 highs as the next support level, near 87.10. Below there was the 50% retracement level near 87.26 and the horizontal support near 84.60.

Source: Tradingview, GAIN Capital

Coronavirus vaccine effect on global stocks

The Dow Jones Industrial Average traded above 30,000 for the first time ever in November. The S&P 500 and NASDAQ are near all-time highs. As the vaccine is introduced to the world population and lockdowns are lifted, we should see a rotation out of “stay at home” stocks and a return to value stocks. Keep in mind however that as the Federal Reserve and other central banks begin to worry less about stimulus and more about inflation in Q3 or Q4, stocks might not be as excited and may begin to turn lower. In the Dow, 32,700 is the 127.2% Fibonacci extension from the highs during the week of February 10^th to the lows the week of March 23^rd:

Source: Tradingview, GAIN Capital

2-year yields forecast

With the introduction of a vaccine to the general public in the first half of the year, 2-year yields should remain between 0%-0.25%. If the word “inflation” enters the FOMC’s vocabulary during this year, rates should turn higher, which may be dramatic as the market tries to price in inflation expectations.

Source: Tradingview, GAIN Capital

Covid 19 vaccine to boost crude oil

As more and more people around the world receive the vaccine, demand for manufacturing will increase. Travel will begin to return to normal and airlines and cruise ships will return to normal operations. The increase in demand could serve as a tailwind for the price for oil. Watch for WTI to continue to move higher as a vaccine is rolled out, possibly testing the January 2020 highs of $65.66.

Source: Tradingview, GAIN Capital

As pharmaceutical companies release more and more of the COVID-19 vaccine, economies should begin to recover, and life will revert to the “old normal”. However, that doesn’t necessarily mean it will be good for the markets as central banks may begin using the words “inflation” and “less stimulus”.

For insight into how tech stocks could perform in 2021, click here.

StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please ensure you fully understand the risks involved by reading our full risk warning.

FOREX.com is a trading name of StoneX Europe Limited, and FOREX.com/ie is a domain operated by StoneX Europe Ltd, a member of StoneX Group Inc. StoneX Europe Ltd, is a Cyprus Investment Firm (CIF) company registered to the Department of Registrar of Companies and Official Receiver with a Registration Number HE409708, and authorized and regulated by the Cyprus Securities & Exchange Commission (CySEC) under license number 400/21. StoneX Europe is a Member of the Investor Compensation Fund (ICF) and has its registered address at Nikokreontos 2, 5th Floor, 1066 Nicosia, Cyprus.

StoneX Europe Limited is registered with the German Federal Financial Supervisory Authority (BaFin). BaFin registration ID: 10160255

FOREX.com is a trademark of StoneX Europe Ltd, a member of StoneX Group Inc.

The statistical data and the awards received refer to the Global FOREX.com brand.

This website uses cookies to provide you with the very best experience and to know you better. By visiting our website with your browser set to allow cookies, you consent to our use of cookies as described in our Privacy Policy.

Through passporting, StoneX Europe is allowed to provide its services and products on a cross-border basis to the following European Economic Area ("EEA") states: Austria, Bulgaria, Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden.

Additionally, StoneX Europe Ltd is allowed to provide Investment and Ancillary Services to the following non-EU jurisdiction: Switzerland.

StoneX Europe Ltd products, services and information are not intended for residents other than the ones stated above.

Tied Agent Information: KQ Markets Europe Ltd with Company No. HE427857.
Address: Athalassas 62, Mezzanine, Strovolos, Nicosia Cyprus.
Services Provided: Reception and Transmission of Orders.
Commencement Date: 06/12/2022
Website: KQ Markets - CFD Trading | KQ Markets

We may pay inducements, such as commissions or fees, to affiliates or third-party introducers for referring clients to us. This is in line with regulatory guidelines and fully disclosed where applicable.

StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation. StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.